Global Thrombosis and Hemostasis Biomarkers Market Size study, by Product Type by Application, by End-user and Regional Forecasts 2024-2032

Description

Global Thrombosis and Hemostasis Biomarkers Market is valued at approximately USD 5.31 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.9% over the forecast period 2024-2032. Thrombosis and hemostasis biomarkers are laboratory parameters derived from the components of the hemostatic system, such as von Willebrand factor (vWF), fibrinogen, D-dimer, and others. These biomarkers are instrumental in detecting certain diseases or their pathophysiological effects and have numerous applications in clinical practice. They offer significant benefits, including the risk estimation and diagnosis of venous thromboembolism (VTE) and other conditions, prediction of thrombotic events in patients with lymphoma, response to chemotherapy in patients with pancreatic cancer, and enhanced patient management.

The growth of the thrombosis and hemostasis biomarkers market is highly attributed to the increased risk of venous thromboembolism (VTE). The risk of VTE is associated with various clinical conditions such as cardiovascular, cerebrovascular, and malignant disorders. In addition, the risk increases with major or minor injuries and obesity. For instance, according to the American Heart Association, Inc. in November 2023, obese individuals have an increased risk of VTE, and the higher the risk becomes as the weight increases. Biomarkers such as D-dimer, fibrinogen, and factor VIII are used to predict the risk of VTE and monitor treatment response. This is expected to significantly boost the adoption of biomarker products, propelling the market growth during the forecast timeframe. Moreover, the growing research initiatives and funding and increasing adoption of biomarkers in clinical practice present various lucrative opportunities over the forecast years. However, the high cost and stringent regulations as well as limitations associated with biomarker use are challenging the market growth throughout the forecast period of 2024-2032.

The key regions considered for the Global Thrombosis and Hemostasis Biomarkers Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global Thrombosis and Hemostasis Biomarkers Market in terms of revenue. The market growth in the area is being attributed to factors including the presence of a highly developed healthcare infrastructure, significant investments in research and development, and the widespread adoption of advanced diagnostic technologies. The United States leads the market due to a high prevalence of cardiovascular diseases and blood disorders, as well as strong collaborations between academic institutions and industry players to develop innovative diagnostic solutions. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising healthcare expenditures, increasing prevalence of thrombotic disorders, and a growing awareness of the importance of early diagnosis and treatment. Countries such as China, India, and Japan are experiencing significant market expansion due to the increasing burden of lifestyle-related diseases, expanding middle-class populations with improved access to healthcare, and government initiatives aimed at enhancing healthcare quality and accessibility.

Major market player included in this report are:

F. Hoffmann-La Roche Ltd
BioMedica Diagnostics
Siemens Healthcare Private Limited
Abbott
HORIBA Medical
BIOMERIEUX
QuidelOrtho Corporation
Stago Group
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Beckman Coulter, Inc.
Sysmex Corporation
Enzo Biochem, Inc.
Diazyme Laboratories, Inc.
Agilent Technologies, Inc.

The detailed segments and sub-segment of the market are explained below:

By Product Type:

Instruments
Reagents & Consumables

By Application:

Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Disseminated Intravascular Coagulation (DIC)
Others

By End-user:

Hospitals & Clinics
Diagnostic Laboratories
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Thrombosis and Hemostasis Biomarkers Market Executive Summary

1.1. Global Thrombosis and Hemostasis Biomarkers Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Product Type
- 1.3.2. By Application
- 1.3.3. By End-user
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Thrombosis and Hemostasis Biomarkers Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Thrombosis and Hemostasis Biomarkers Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Prevalence of Venous Thromboembolism (VTE)
- 3.1.2. Advances in Cancer Diagnosis and Treatment
3.2. Market Challenges
- 3.2.1. High Cost and Stringent Regulations
- 3.2.2. Limitations Associated with Biomarker Use
3.3. Market Opportunities
- 3.3.1. Growing Research Initiatives and Funding
- 3.3.2. Increasing Adoption of Biomarkers in Clinical Practice

Chapter 4. Global Thrombosis and Hemostasis Biomarkers Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Thrombosis and Hemostasis Biomarkers Market Size & Forecasts by Product Type 2022-2032

5.1. Segment Dashboard
5.2. Global Thrombosis and Hemostasis Biomarkers Market: Product Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Instruments
- 5.2.2. Reagents & Consumables

Chapter 6. Global Thrombosis and Hemostasis Biomarkers Market Size & Forecasts by Application 2022-2032

6.1. Segment Dashboard
6.2. Global Thrombosis and Hemostasis Biomarkers Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Deep Vein Thrombosis (DVT)
- 6.2.2. Pulmonary Embolism (PE)
- 6.2.3. Disseminated Intravascular Coagulation (DIC)
- 6.2.4. Others

Chapter 7. Global Thrombosis and Hemostasis Biomarkers Market Size & Forecasts by End-user 2022-2032

7.1. Segment Dashboard
7.2. Global Thrombosis and Hemostasis Biomarkers Market: End-user Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospitals & Clinics
- 7.2.2. Diagnostic Laboratories
- 7.2.3. Others

Chapter 8. Global Thrombosis and Hemostasis Biomarkers Market Size & Forecasts by Region 2022-2032

8.1. North America Thrombosis and Hemostasis Biomarkers Market
- 8.1.1. U.S. Thrombosis and Hemostasis Biomarkers Market
  - 8.1.1.1. Product Type breakdown size & forecasts, 2022-2032
  - 8.1.1.2. Application breakdown size & forecasts, 2022-2032
  - 8.1.1.3. End-user breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Thrombosis and Hemostasis Biomarkers Market
8.2. Europe Thrombosis and Hemostasis Biomarkers Market
- 8.2.1. U.K. Thrombosis and Hemostasis Biomarkers Market
- 8.2.2. Germany Thrombosis and Hemostasis Biomarkers Market
- 8.2.3. France Thrombosis and Hemostasis Biomarkers Market
- 8.2.4. Spain Thrombosis and Hemostasis Biomarkers Market
- 8.2.5. Italy Thrombosis and Hemostasis Biomarkers Market
- 8.2.6. Rest of Europe Thrombosis and Hemostasis Biomarkers Market
8.3. Asia-Pacific Thrombosis and Hemostasis Biomarkers Market
- 8.3.1. China Thrombosis and Hemostasis Biomarkers Market
- 8.3.2. India Thrombosis and Hemostasis Biomarkers Market
- 8.3.3. Japan Thrombosis and Hemostasis Biomarkers Market
- 8.3.4. Australia Thrombosis and Hemostasis Biomarkers Market
- 8.3.5. South Korea Thrombosis and Hemostasis Biomarkers Market
- 8.3.6. Rest of Asia Pacific Thrombosis and Hemostasis Biomarkers Market
8.4. Latin America Thrombosis and Hemostasis Biomarkers Market
- 8.4.1. Brazil Thrombosis and Hemostasis Biomarkers Market
- 8.4.2. Mexico Thrombosis and Hemostasis Biomarkers Market
- 8.4.3. Rest of Latin America Thrombosis and Hemostasis Biomarkers Market
8.5. Middle East & Africa Thrombosis and Hemostasis Biomarkers Market
- 8.5.1. Saudi Arabia Thrombosis and Hemostasis Biomarkers Market
- 8.5.2. South Africa Thrombosis and Hemostasis Biomarkers Market
- 8.5.3. Rest of Middle East & Africa Thrombosis and Hemostasis Biomarkers Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. F. Hoffmann-La Roche Ltd
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. BioMedica Diagnostics
- 9.3.3. Siemens Healthcare Private Limited
- 9.3.4. Abbott
- 9.3.5. HORIBA Medical
- 9.3.6. BIOMERIEUX
- 9.3.7. QuidelOrtho Corporation
- 9.3.8. Stago Group
- 9.3.9. Thermo Fisher Scientific Inc.
- 9.3.10. Bio-Rad Laboratories, Inc.
- 9.3.11. Beckman Coulter, Inc.
- 9.3.12. Sysmex Corporation
- 9.3.13. Enzo Biochem, Inc.
- 9.3.14. Diazyme Laboratories, Inc.
- 9.3.15. Agilent Technologies, Inc.

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes